前臨床CROの世界市場規模：サービス別、用途別、エンドユーザー別、地域別、範囲および予測

前臨床CROの市場規模と予測

前臨床CRO市場規模は、2023年に54億4,000万米ドルと評価され、2024年から2031年にかけてCAGR 8.03%で成長し、2031年には101億米ドルに達すると予測されています。前臨床試験受託機関（CRO）は、新薬や治療法をヒト臨床試験に移行する前に調査や実験を行う、製薬やバイオテクノロジー研究の専門サービスプロバイダーです。前臨床CROは医薬品開発の初期段階において重要な役割を果たし、新規化合物の安全性、有効性、毒性の可能性を判断するための非ヒト試験に重点を置いています。これらの組織は、in vitroおよびin vivo試験、薬物動態学、毒性学的研究など、様々なサービスを提供しています。

さらに、前臨床研究をCROに委託する製薬企業やバイオテクノロジー企業は、次のようなサービスを提供しています。

前臨床CRO市場力学

前臨床CRO市場を形成している主な市場力学

主な市場促進要因

医薬品開発の複雑化：

医薬品開発の複雑化：複雑な疾患や治療標的をより深く理解するため、製薬業界は専門的な前臨床研究サービスに注力しています。そのため、高度な設備と専門チームを備えた前臨床CROは、医薬品開発の複雑性を解決し、研究の初期段階をスピードアップする斬新なソリューションを提供する上で重要な役割を果たしています。その結果、医薬品開発の複雑性が増していることが、前臨床CRO市場の拡大を後押しする重要な要因となっています。

アウトソーシングの効率化：

製薬企業やバイオテクノロジー企業は、医薬品開発プロセスを合理化するため、CRO（医薬品開発業務受託機関）の利用を増やしています。この戦略的アウトソーシングにより、これらの企業は前臨床CRO特有のスキルや費用対効果を活用しながら、自社のコアとなる強みに集中することができます。このようなアウトソーシングへの傾向は、CROがもたらす価値を業界が認識し、より効率的な資源配分と迅速なターンアラウンドを可能にしていることを示しています。

調査ツールの技術的進歩：

調査手法の絶え間ない進化は、イメージング技術や分子生物学ツールの進歩とともに前臨床CROの能力を高め、前臨床CRO市場の成長を促進しています。最先端技術の使用により、これらの企業はより正確で効率的な前臨床試験を実施し、医薬品開発プロセスを改善することができます。このように、研究機器の技術開発は、前臨床CROの状況を定義する重要な要因です。

主な課題

長い薬事承認スケジュール：

薬事承認に必要な追加期間が、前臨床段階を迅速に進めようとする企業の妨げとなっています。承認の遅れは開発プロセスを遅らせ、製薬会社のコストと不確実性を増大させ、医薬品開発のタイムテーブルに大きな制約をもたらします。

データのセキュリティと機密性の問題：

前臨床研究データのデリケートな性質は、データのセキュリティと機密性に関する懸念が、医薬品開発の重要な段階を外部に委託することを企業に躊躇させるため、大きな制約となります。知的財産の盗難や機密情報への不正アクセスの脅威は、前臨床CRO市場において大きな障害となっています。

限られたキャパシティとリソース：

製薬業界における前臨床CROサービスに対するリソース需要の高まりに対応できないことが、前臨床CROサービスの採用を阻害すると予測されます。また、可用性の制限や遅延は製薬ビジネスに大きな影響を与えます。さらに、特定の専門CROの希少性は、特に独自の専門知識が必要とされる場合、コラボレーションの機会を制限します。

主要動向

治療領域の拡大：

治療領域の拡大は、前臨床CROサービスの需要を急増させる可能性が高いです。前臨床CROは、がんのような従来の重点分野にとどまらず、神経学や一般的でない疾患にも専門性を拡大しつつあり、これは市場の大きな動向となっています。また、前臨床CROは様々な治療領域に適応し、専門性を高めており、医薬品開発戦略全体の戦略的パートナーとしての役割を強化しています。

バイオマーカー開発：

バイオマーカー開発の重視は、治療に対する患者の反応を個別化するという意識の高まりに対応する変革的な傾向です。前臨床CROはこの革命の先陣を切り、バイオマーカーの同定と検証に積極的に取り組んでいます。この戦略的戦略により、より的を絞った投薬研究が可能となり、また、これらの事業が将来のオーダーメードヘルスケアに不可欠なアクターとして位置づけられ、前臨床CROに対するより高い需要を生み出しています。

前臨床CRO市場の地域分析

前臨床CRO市場の詳細な地域分析は以下の通りです：

北米

Verified Market Researchによると、予測期間中、アジア太平洋地域が前臨床CRO市場で優位を占めると予測されています。製薬会社が医薬品や治療法の開発に注力し、厳格な規制構造に準拠した前臨床CROサービスを実施していることが、北米における前臨床の膨大な応用を可能にしています。

同地域では、医薬品開発を管理する厳しい規制により、前臨床CROサービスに対する大きな需要が発生しています。これらのサービスは、厳格な規制基準への準拠を保証し、患者の安全性への献身を示し、製薬研究における最高レベルの有効性を維持する上で極めて重要です。厳しい規制の枠組みは、北米を前臨床研究の著名な拠点として際立たせ、医薬品開発のための規制に準拠した透明性の高いアプローチを求める企業を惹きつけています。

さらに、多数の製薬企業やバイオテクノロジー企業が集積していることも、この地域の前臨床研究の優位性に寄与しています。これらの業界関係者が近接しているため、前臨床研究活動が集中するダイナミックなエコシステムが形成されています。このような集積効果により、製薬企業と確立された前臨床CROとの間の交流が容易になっています。

欧州

欧州の前臨床CRO市場は、創薬と治療の分野でイノベーションを生み出す最前線にあり、それによって製薬研究の進展につながっています。欧州は、バイオテクノロジーセクターの繁栄、政府の積極的な取り組み、前臨床CRO市場におけるアウトソーシング傾向の拡大により、前臨床研究の軌道を決定する重要なプレーヤーとして台頭してきました。

この地域では、新薬やバイオ医薬品への注目が高まっており、前臨床専門サービスへの需要が高まっています。欧州企業が最先端のバイオテクノロジーの進歩に力を入れるにつれ、包括的な前臨床研究の必要性が高まっています。その結果、欧州における治療法の進歩が期待されます。

さらに、製薬会社における前臨床CROのアウトソーシング需要の高まりは、欧州市場に開拓の機会をもたらしています。医薬品開発の初期段階における専門知識と費用対効果のメリットを認識し、欧州の製薬企業は前臨床CROとの提携を積極的に進めています。この戦略的な動きにより、企業はCROが提供する専門的なサービスを活用しながら、中核的な能力に集中して業務を合理化することができます。

アジア太平洋

アジア太平洋地域は、予測期間中、前臨床CRO市場において最も高いCAGRで成長すると推定されます。アジア太平洋地域の前臨床CRO市場は、慢性疾患の高い蔓延により急速に拡大しており、効率的な治療とバイオ医薬品の需要が急増しています。これに加えて、バイオ医薬品企業の開発とともにヘルスケア支出が増加しているため、多様な患者が集まり、前臨床CROサービスの採用範囲が広がっています。

アジア太平洋地域のヘルスケア支出は、特に中国やインドのような人口の多い国々で大幅に増加しています。このような投資の増加は、製薬およびバイオテクノロジー産業の勃興に拍車をかけています。前臨床CROサービスに対する需要は、この地域におけるこれらの分野の拡大と並行して増加しています。

さらに、アジア太平洋諸国に存在する多様な民族性と人口統計は、前臨床研究に貴重なリソースを提供しています。この地域の前臨床CROと連携する製薬企業は、民族を超えた薬物反応を試験する能力から恩恵を受け、その結果、新薬候補の有効性と安全性プロファイルをより深く理解することができます。このように、アジア太平洋地域は患者集団の多様性から、前臨床CRO市場拡大のための肥沃な大地となりつつあり、世界の医薬品開発手法に影響を与える可能性が高いです。

目次

第1章 世界の前臨床市場イントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• 検証
• 一次資料
• データソース一覧

第4章 世界の前臨床市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 世界の前臨床市場：サービス別

• 概要
• バイオアナリシスおよび薬物代謝・薬物動態（DMPK）試験
• 毒性試験

第6章 前臨床試験の世界市場：エンドユーザー別

• 概要
• 製薬・バイオ製薬企業
• 医療機器企業
• 学術機関

第7章 世界の前臨床市場、用途別

• 概要
• 腫瘍学
• 中枢神経系（CNS）疾患
• 心血管疾患
• 免疫疾患
• 呼吸器疾患
• 感染症
• 糖尿病
• その他

第8章 前臨床試験の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の前臨床市場競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第10章 企業プロファイル

• Charles River Laboratories
• Syneos Health
• WuXi AppTec
• Eurofins Scientific
• Envigo
• Covance
• Parexel
• Labcorp Drug Development
• Emmes Corporation

第11章 主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第12章 付録

• 関連調査

Preclinical CRO Market Size And Forecast

Preclinical CRO Market size was valued at USD 5.44 Billion in 2023 and is projected to reach USD 10.1 Billion by 2031, growing at a CAGR of 8.03% from 2024 to 2031. A preclinical Contract Research Organization (CRO) is a specialist service provider in pharmaceutical and biotechnological research that conducts investigations and experiments before moving a new medicine or medical treatment into human clinical trials. Preclinical CROs serve an important role in the early stages of drug development, focusing on non-human testing to determine the safety, effectiveness, and possible toxicity of novel compounds. These organizations offer a variety of services, including in vitro and in vivo testing, pharmacokinetics, and toxicological research.

Furthermore, pharmaceutical and biotech companies that outsource preclinical research to CROs

Preclinical CRO Market Dynamics

The key market dynamics that are shaping the Preclinical CRO Market include:

Key Market Drivers

Increasing Complexity in Drug Development:

To gain a better understanding of complex diseases and treatment targets, the pharmaceutical industries are focusing on specialized preclinical research services. Thus, preclinical CROs, equipped with advanced equipment and professional teams, play a critical role in resolving the complexity of drug development, providing novel solutions to speed up the early stages of research. As a result, the increasing complexity of drug development is a significant driver fueling the expansion of the Preclinical CRO Market.

Outsourcing Efficiency:

Pharmaceutical and biotech companies are increasingly using contract research organizations (CROs) to streamline the drug development process. This strategic outsourcing enables these businesses to focus on their core strengths while taking advantage of preclinical CROs' specific skills and cost-effectiveness. This inclination toward outsourcing demonstrates the industry's recognition of the value that CROs bring to the table, allowing for more efficient resource allocation and faster turnaround.

Technological Advancements in Research Tools:

The constant evolution of research methodology, together with advances in imaging techniques and molecular biology tools is enhancing the capabilities of preclinical CROs, propelling the growth of the Preclinical CRO Market. The use of cutting-edge technologies enables these firms to undertake more precise and efficient preclinical examinations to improve their drug development processes. Thus, technological developments in research instruments are an important factor defining the preclinical CRO landscape.

Key Challenges

Long Regulatory Approval Timelines:

The additional period required for regulatory clearance hampers companies looking to move fast through the preclinical phase. Delays in approvals delay the development process and also increase pharmaceutical companies' costs and uncertainties, posing a significant constraint on the total drug development timetable.

Data Security and Confidentiality Issues:

The delicate nature of preclinical research data creates a significant constraint as concerns regarding data security and confidentiality discourage corporations from outsourcing vital stages of drug development. This threat of intellectual property theft or illegal access to confidential information poses a significant impediment in the Preclinical CRO Market.

Limited Capacity and Resources:

The inability to meet the rising demand for resources for preclinical CRO services in the pharmaceutical industry is projected to inhibit the adoption of preclinical CRO services. Also, the limited availability or delays further have a huge impact on the pharmaceutical businesses. Furthermore, the scarcity of certain specialized CROs limits collaboration opportunities, particularly when unique expertise is required.

Key Trends

Expansion of Therapeutic Areas:

The growth of therapeutic domains is likely to surge the demand for preclinical CRO services. Preclinical CROs are expanding their expertise beyond conventional emphasis areas like cancer and into neurology and uncommon disorders representing a significant trend in the market. Also, preclinical CROs' ability to adapt to and increase their expertise in a variety of therapeutic areas strengthens their role as strategic partners in overall drug development strategy.

Biomarker Development:

The emphasis on biomarker development is a transformative trend that corresponds to the growing awareness of personalized patient responses to therapies. Preclinical CROs are at the vanguard of this revolution, actively identifying and validating biomarkers. This strategic strategy allows for more targeted and successful medication research and also places these businesses as essential actors in the future of customized healthcare, creating higher demand for preclinical CRO.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Preclinical CRO Market Regional Analysis

Here is a more detailed regional analysis of the Preclinical CRO Market:

North America

According to Verified Market Research, Asia Pacific is estimated to dominate in Preclinical CRO Market over the forecast period. The focus of pharmaceutical companies on developing drugs, treatments, and implementing preclinical CRO services compliant with strict regulatory structure is enabling in creating vast application of preclinical in North America..

The region is experiencing significant demand for preclinical CRO services due to the strict regulations governing drug development. These services are critical in guaranteeing compliance with stringent regulatory standards, demonstrating dedication to patient safety and maintaining the highest levels of efficacy in pharmaceutical research. The tight regulatory framework distinguishes North America as a prominent hub for preclinical research, attracting companies seeking a regulatory-compliant and transparent approach for drug development.

Furthermore, the concentration of a large number of pharmaceutical and biotech companies contributes to the region's preclinical research dominance. The proximity of these industry participants has resulted in a dynamic ecosystem, with a high concentration of preclinical research activity. This clustering effect allows for easy interactions between pharmaceutical corporations and established preclinical CROs.

Europe

Europe's Preclinical CRO Market is at the forefront of generating innovation in the field of drug discovery and treatment, thereby leading to the progression of pharmaceutical research. Europe has emerged as an important player in defining the trajectory of preclinical research, owing to a thriving biotechnology sector, favorable government efforts, and an expanding tendency of outsourcing in the Preclinical CRO Market.

The region's increased focus on novel medicines and biopharmaceuticals has increased demand for specialist preclinical services. As European corporations focus more on cutting-edge biotechnological advancements, the need for comprehensive preclinical research grows. This is likely to result in the advancements of therapeutics in Europe.

Furthermore, the growing demand for outsourcing of preclinical CRO in pharmaceutical companies is creating development opportunities for the market in Europe. Recognizing the benefits of specialized expertise and cost-effectiveness in the early stages of drug development, European pharmaceutical companies are actively collaborating with preclinical CROs. This strategic move enables businesses to streamline their operations, focusing on core capabilities while leveraging the specialized services provided by CRO.

Asia Pacific

Asia Pacific is estimated to grow at the highest CAGR in the Preclinical CRO Market during the forecast period. The Preclinical CRO Market in Asia Pacific is expanding rapidly owing to the high prevalence of chronic illnesses, which is surging the demand for efficient treatment and biopharmaceuticals. In addition to this, the increasing healthcare spending along with the development of biopharmaceutical companies is attracting diverse patient population, creating a wider scope of adoption for the preclinical CRO services.

Healthcare expenditure in Asia-Pacific is increasing significantly, particularly in populous countries like China and India. This increasing investment has fueled the rise of the pharmaceutical and biotech industries. This demand for preclinical CRO services increases in parallel with the expansion of these sectors in this region.

Furthermore, the diverse ethnicities and demographics that exist in Asia Pacific countries provide an invaluable resource for preclinical research. Pharmaceutical companies that work with preclinical CROs in this region benefit from the capacity to test medication reactions across ethnicities, resulting in a more thorough understanding of a drug candidate's efficacy and safety profile. Because of the diversity of patient populations, Thus, Asia Pacific is turning into a fertile ground for the expansion of the Preclinical CRO Market that is likely to influence worldwide drug development methods.

Global Preclinical CRO Market Segmentation Analysis

The Global Preclinical CRO Market is segmented on the basis of Service, Application, End-User, And Geography.

Preclinical CRO Market, By Service

• Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies
• Toxicology Testing

Based on Service, the market is segmented into Bioanalysis & DMPK Studies and Toxicology Testing. The Toxicology Testing segment is estimated to dominate the Preclinical CRO Market due to its critical role in assessing the safety and potential toxicity of new drug candidates. Toxicology testing is an essential part of the preclinical review process, providing critical information on the negative effects a substance may have on biological systems. As regulatory authorities prioritize comprehensive safety assessments before clinical trials, pharmaceutical and biotech businesses are increasingly relying on CROs for specialist toxicology testing services. These services cover a wide range of investigations, including acute, sub-chronic, and chronic toxicity assessments, as well as reproductive and developmental toxicology research. The importance of toxicological testing reflects its critical role in guaranteeing the overall safety profile of drug candidates, reducing risks and increasing the possibility of achieving regulatory approval in later clinical phases.

Preclinical CRO Market, By Application

• Oncology
• Central Nervous System (CNS) Disorders
• Cardiovascular Diseases
• Immunological Disorders
• Respiratory Diseases
• Infectious Diseases
• Diabetes
• Others

Based on Application, the market is segmented into Oncology, Central Nervous System (CNS) Disorders, Cardiovascular Diseases, Immunological Disorders, Respiratory Diseases, Infectious Diseases, Diabetes, and Others. The Oncology segment is estimated to dominate the Preclinical CRO Market. Oncology has seen an increase in demand for preclinical CRO services because of the complexities and obstacles of finding effective cancer medicines is increasing the application of preclinical CRO in oncology.

• Preclinical CROs that specialize in oncology conduct critical research such as efficacy assessments, toxicity evaluations, and biomarker discovery to help create innovative and tailored medicines. The complexities of cancer biology require specialized expertise, cutting-edge technologies, and a thorough understanding of regulatory regulations, all of which is likely to be provided by preclinical CROs. Their ability to manage the complexities of oncology research, combined with the rising worldwide cancer incidence and the ongoing hunt for novel treatments, positions the oncology application segment as the primary driver driving the growth and significance of the entire Preclinical CRO Market.

Preclinical CRO Market, By End-User

• Pharmaceutical and Biopharmaceutical Industries
• Medical Device Companies
• Academic Institutes

Based on End-User, the market is segmented into Pharmaceutical & Biopharmaceutical Industries, Medical Device Companies, and Academic Institutes. The pharmaceutical and biopharmaceutical industries end-user segment is estimated to dominate the market over the forecast period. Pharmaceutical and biopharmaceutical companies are depending more and more on the specialized services provided by preclinical CROs to help them negotiate the challenging early stages of drug development as the market for innovative and focused therapeutics grows. These sectors necessitate extensive preclinical testing, including efficacy, safety, and toxicity investigations, to guarantee that new drug candidates meet tight regulatory requirements. Outsourcing preclinical research efforts to CROs enables pharmaceutical and biopharmaceutical companies to benefit from external knowledge, cutting-edge technologies, and cost-effective solutions, accelerating the drug development process.

Key Players

• The "Global Preclinical CRO Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as
• Charles River Laboratories, Syneos Health, WuXi AppTec, Eurofins Scientific, Envigo, Covance, Parexel, Labcorp Drug Development, Emmes Corporation, Albany Molecular Research Inc., Aptuit LLC, Bio-Bridge Laboratories Inc., Stelis Biopharma, ToxStrategies Inc., Epredia, Marshall BioResources, Taconic Biosciences, Xenotech and Evotec.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In January 2024, WuXi AppTec, a renowned Chinese CRO, collaborated with Personalis, a genomics data business, to develop AI-powered drug discovery solutions. The collaboration hopes to use Personalis' AI technology to scan massive amounts of genomic data and find new therapeutic targets.
• In January 2024, Charles River Laboratories, a global leader in preclinical CRO services, announced an expansion of its bioanalytical capabilities in Europe. The company bought a bioanalytical laboratory in the United Kingdom, expanding its drug development support services.
• In January 2024, Syneos Health, a well-known clinical CRO, partnered with Huma Therapeutics, a digital health business, to create digital biomarkers for Parkinson's disease. This cooperation intends to use wearable technologies and artificial intelligence to monitor illness development and improve clinical trial design.
• In January 2024, Eurofins Scientific, a prominent provider of analytical testing services, acquired Bio-Alternatives, a preclinical drug discovery CRO. This acquisition broadens Eurofins' expertise in fields such as in vitro toxicity and ADME investigations.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PRECLINICAL CRO MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PRECLINICAL CRO MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL PRECLINICAL CRO MARKET, BY SERVICE

• 5.1 Overview
• 5.2 Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies
• 5.3 Toxicology Testing

6 GLOBAL PRECLINICAL CRO MARKET, BY END-USER

• 6.1 Overview
• 6.2 Pharmaceutical and Biopharmaceutical Industries
• 6.3 Medical Device Companies
• 6.4 Academic Institutes

7 GLOBAL PRECLINICAL CRO MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Oncology
• 7.3 Central Nervous System (CNS) Disorders
• 7.4 Cardiovascular Diseases
• 7.5 Immunological Disorders
• 7.6 Respiratory Diseases
• 7.7 Infectious Diseases
• 7.8 Diabetes
• 7.9 Others

8 GLOBAL PRECLINICAL CRO MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL PRECLINICAL CRO MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Charles River Laboratories
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Syneos Health
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 WuXi AppTec
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Eurofins Scientific
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Envigo
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Covance
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Parexel
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Labcorp Drug Development
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Emmes Corporation
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research